David W. Nassif - 08 Feb 2022 Form 4 Insider Report for Sio Gene Therapies Inc.

Role
Interim CEO, CFO, Director
Signature
/s/ David Nassif
Issuer symbol
N/A
Transactions as of
08 Feb 2022
Net transactions value
$0
Form type
4
Filing time
10 Feb 2022, 16:05:27 UTC
Previous filing
09 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SIOX Restricted Stock Units Award $0 +546,500 $0.000000 546,500 08 Feb 2022 Common Stock 546,500 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
F2 One-third of the restricted stock units shall vest on February 8, 2023, February 8, 2024 and February 8, 2025, subject to the Reporting Person providing continuous service to the Issuer through each such date.